IPA
NASDAQImmunoPrecise Antibodies Ltd.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.09+1.50 (+256.90%)
2025-06-042025-09-03
News · 26 weeks2+100%
2025-12-072026-05-31
Mix290d
- Other1(50%)
- Leadership1(50%)
Latest news
25 items- PRInterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of DirectorsSOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ -- InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases. "We are excited to welcome Alec and Mitch to InterVenn's Board of Directors at a pivotal moment fo
- PRThe Biology Came First.Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today. MindWalk Holdings Corp. (NASDAQ:HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT"An Evolution in Name, Structure, and Strategy Reflecting the Company's AI-Driven Platform and Bio-Native Discovery Vision ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announced a unification under a single corporate brand, MindWalk, and a change of its Nasdaq ticker symbol to HYFT. The new identity conveys the Company's evolution into a Bio-Native AI platform business built at the intersection of AI, multi-omics data, and advanced laboratory research. "Today is an evolutionary step forward," said Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk. "Inspired by Darwin'
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New YorkImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025. Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Event Details: Conference: 27th Annual H.C. Wainwright Global Investment Conference Date: September 8-10th, 2025 Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email meetings@hcwco.com About ImmunoPrecise Antibodies Ltd.
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody GenerationManufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the Company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralizatio
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI InnovationImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe"), to AVS Bio for a total enterprise value of $12 million USD. AVS Bio, a portfolio company of Arlington Capital Partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. The transaction generated $11.7 million USD in net proceeds on a cash-free, debt-free basis. This transaction marks a meaningful step in IPA's strategic refinement—streamlining its o
- PRAVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe" or the "Company"). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai™ platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bio's European footprint and adds advanced capabilities in antibody
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDAImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180
- SECSEC Form 20-F filed by ImmunoPrecise Antibodies Ltd.20-F - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the ClinicImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-ri
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory BoardImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve
- PRIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
- PRImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of DirectorsImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded
- SECSEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
IPA FAQ
6 questionsWhat does ImmunoPrecise Antibodies Ltd. do?
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species...Where does IPA stock trade?
ImmunoPrecise Antibodies Ltd. (IPA) is listed on NASDAQ.What sector and industry is IPA in?
ImmunoPrecise Antibodies Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IPA?
ImmunoPrecise Antibodies Ltd. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2022-12-02. Recent price targets range from $900.00 to $1200.00.What companies are similar to IPA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IPA side-by-side with any of them on Quantisnow.How can I track IPA on Quantisnow?
Quantisnow aggregates ImmunoPrecise Antibodies Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IPA to receive live email and push alerts on every new disclosure.